Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHN Achillion Pharmaceuticals	$6.76	$6.76	$2.06 ▼ $7.01	$946.72M	1.59	8.44 million shs	N/A
APRE Aprea Therapeutics	$1.66 -0.6%	$1.74	$1.41 ▼ $5.01	$9.24M	1.19	27,974 shs	93,479 shs
KNSA Kiniksa Pharmaceuticals International	$29.02 +0.6%	$27.90	$17.82 ▼ $30.69	$2.10B	0.05	558,527 shs	841,396 shs
RYTM Rhythm Pharmaceuticals	$89.20 -1.6%	$67.14	$40.61 ▼ $94.80	$5.77B	2.26	590,318 shs	624,068 shs
STOK Stoke Therapeutics	$13.22 +7.0%	$10.89	$5.35 ▼ $16.15	$674.27M	1.14	678,585 shs	1.55 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHN Achillion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+754.41%
APRE Aprea Therapeutics	+0.60%	-5.65%	-4.84%	+11.30%	-58.15%
KNSA Kiniksa Pharmaceuticals International	+1.48%	-0.38%	+3.18%	+42.70%	+34.70%
RYTM Rhythm Pharmaceuticals	-0.83%	+1.84%	+46.33%	+46.87%	+74.12%
STOK Stoke Therapeutics	+3.78%	+2.57%	+5.92%	+60.60%	-9.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHN Achillion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
APRE Aprea Therapeutics	2.9391 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.8	1.3
KNSA Kiniksa Pharmaceuticals International	3.3535 of 5 stars	3.5	4.0	0.0	0.0	2.1	3.3	0.6
RYTM Rhythm Pharmaceuticals	3.1928 of 5 stars	2.5	1.0	0.0	4.3	2.6	0.8	0.6
STOK Stoke Therapeutics	4.2311 of 5 stars	3.6	1.0	0.0	4.8	3.0	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHN Achillion Pharmaceuticals	0.00	N/A	N/A	N/A
APRE Aprea Therapeutics	3.00	Buy	$15.50	833.73% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$39.33	35.54% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.93	3.06% Upside
STOK Stoke Therapeutics	3.29	Buy	$25.80	95.16% Upside

Current Analyst Ratings Breakdown

Latest RYTM, APRE, KNSA, ACHN, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$92.00 ➝ $105.00
7/18/2025	STOK Stoke Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHN Achillion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
APRE Aprea Therapeutics	$1.50M	6.12	N/A	N/A	$3.55 per share	0.47
KNSA Kiniksa Pharmaceuticals International	$423.24M	5.00	N/A	N/A	$6.60 per share	4.40
RYTM Rhythm Pharmaceuticals	$130.13M	43.61	N/A	N/A	$0.35 per share	254.86
STOK Stoke Therapeutics	$36.56M	19.74	N/A	N/A	$4.32 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHN Achillion Pharmaceuticals	-$70.27M	-$0.51	N/A	N/A	N/A	N/A	-30.95%	-29.09%	N/A
APRE Aprea Therapeutics	-$12.96M	-$2.37	0.00	N/A	N/A	-1,095.02%	-68.39%	-55.74%	8/11/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	116.08	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	0.00	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	15.63	N/A	N/A	26.33%	19.08%	15.72%	8/6/2025 (Estimated)

Latest RYTM, APRE, KNSA, ACHN, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	STOK Stoke Therapeutics	-$0.0905	N/A	N/A	N/A	$31.51 million	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	APRE Aprea Therapeutics	-$0.6543	-$0.66	-$0.0057	-$0.66	N/A	$0.16 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHN Achillion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHN Achillion Pharmaceuticals	0.01	8.96	8.96
APRE Aprea Therapeutics	N/A	5.90	5.90
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHN Achillion Pharmaceuticals	79.42%
APRE Aprea Therapeutics	34.19%
KNSA Kiniksa Pharmaceuticals International	53.95%
RYTM Rhythm Pharmaceuticals	N/A
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ACHN Achillion Pharmaceuticals	4.58%
APRE Aprea Therapeutics	13.63%
KNSA Kiniksa Pharmaceuticals International	53.48%
RYTM Rhythm Pharmaceuticals	6.10%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHN Achillion Pharmaceuticals	56	140.05 million	N/A	Optionable
APRE Aprea Therapeutics	7	5.53 million	4.78 million	No Data
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

RYTM, APRE, KNSA, ACHN, and STOK Headlines

Recent News About These Companies

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up - What's Next?

July 18 at 12:03 PM | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Now Covered by Analysts at Jefferies Financial Group

July 18 at 9:31 AM | marketbeat.com

Epilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

July 15 at 10:23 PM | theglobeandmail.com

Stoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years ago

July 15 at 10:37 AM | finance.yahoo.com

The charming Stoke-on-Trent four-bed family home that's 'ready to be lived in'

July 13, 2025 | msn.com

New Royal Stoke technology cuts hospital stays by over a day

July 13, 2025 | msn.com

Stoke City Boss Delighted To Finally Get Signing Over The Line

July 13, 2025 | therealefl.co.ukT

Grit bin raiders and double parking hinders work to keep Stoke-on-Trent moving in winter

July 13, 2025 | msn.com

Five of the best beer gardens around Stoke-on-Trent to enjoy in the sun

July 13, 2025 | msn.com

Man City prospect told to gain notoriety at Stoke City

July 13, 2025 | msn.com

Case builds for Biogen, Stoke's Dravet syndrome drug

July 11, 2025 | pharmaphorum.comP

Lille rival Aston Villa in race for Stoke’s Sol Sidibé

July 10, 2025 | sports.yahoo.com

Aston Villa want Stoke City midfielder Sol Sidibe

July 10, 2025 | sports.yahoo.com

Stoke City vs Shrewsbury LIVE Score Updates: Match Canceled

July 10, 2025 | vavel.comV

Council still against Stoke-on-Trent 'merger' as devolution decision gets nearer

July 10, 2025 | msn.com

Live updates after 'accident' on Stoke-on-Trent road

July 10, 2025 | stokesentinel.co.ukS

Stoke City close in on fourth summer signing

July 10, 2025 | msn.com

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10, 2025 | globenewswire.com

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10, 2025 | businesswire.com

Live updates as firefighters on scene of Stoke-on-Trent blaze

July 8, 2025 | stokesentinel.co.ukS

Police helicopter tracks 4 masked kids on stolen motorbikes in Stoke-on-Trent park

July 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM, APRE, KNSA, ACHN, and STOK Company Descriptions

Achillion Pharmaceuticals NASDAQ:ACHN

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Aprea Therapeutics NASDAQ:APRE

$1.66 -0.01 (-0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 +0.05 (+2.71%)

As of 04:56 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$29.02 +0.18 (+0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$29.05 +0.03 (+0.10%)

As of 05:23 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Rhythm Pharmaceuticals NASDAQ:RYTM

$89.20 -1.48 (-1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$90.39 +1.19 (+1.33%)

As of 07:55 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$13.22 +0.87 (+7.04%)

Closing price 04:00 PM Eastern

Extended Trading

$13.54 +0.32 (+2.46%)

As of 06:43 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time